Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

643
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
643
Genetic Lingo01:11

Genetic Lingo

117.1K
Overview
117.1K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preface to special issue on neurodevelopment in Huntington's disease.

Journal of Huntington's disease·2026
Same author

Clinical implications of loss of interruption variants for diagnosis, genetic counselling, and clinical trials in Huntington's disease.

Journal of Huntington's disease·2026
Same author

Classical and Emerging Biomarkers in Pyridoxine-Dependent Epilepsy (PDE-ALDH7A1): Implications for Early Diagnosis and Therapeutic Development.

Biomolecules·2026
Same author

Humanized mice carrying a pathogenic GRN deletion as a pre-clinical platform for targeted gene therapies in frontotemporal dementia.

Neurobiology of disease·2026
Same author

Progranulin genetic variant rs5848 displays ancestry-specific associations with Alzheimer's disease.

Human genomics·2026
Same author

Wild-type huntingtin in neurodevelopment.

Journal of Huntington's disease·2026
Same journal

Accidental hypothermia.

Nature reviews. Disease primers·2026
Same journal

Accidental hypothermia.

Nature reviews. Disease primers·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Buruli ulcer in Africa: between innovation and pragmatism.

Nature reviews. Disease primers·2026
Same journal

Author Correction: Atopic dermatitis.

Nature reviews. Disease primers·2026
See all related articles

Related Experiment Video

Updated: Mar 21, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

10.1K

Huntington disease.

Gillian P Bates1, Ray Dorsey2, James F Gusella3

  • 1Department of Medical and Molecular Genetics, King's College London, London, UK.

Nature Reviews. Disease Primers
|May 19, 2016
PubMed
Summary
This summary is machine-generated.

Huntington disease, caused by expanded CAG repeats in the HTT gene, leads to progressive motor, cognitive, and behavioral decline. Research is advancing on understanding its pathogenesis and developing targeted therapies, including huntingtin-lowering drugs.

More Related Videos

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
10:52

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System

Published on: December 10, 2021

3.1K
Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease
09:06

Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease

Published on: June 9, 2018

12.7K

Related Experiment Videos

Last Updated: Mar 21, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

10.1K
Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
10:52

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System

Published on: December 10, 2021

3.1K
Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease
09:06

Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease

Published on: June 9, 2018

12.7K

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Huntington disease (HD) is an autosomal dominant neurodegenerative disorder.
  • It is characterized by motor, cognitive, and behavioral impairments.
  • HD is caused by an expanded CAG trinucleotide repeat in the HTT gene, leading to mutant huntingtin protein with toxic gain of function.

Purpose of the Study:

  • To provide a comprehensive review of Huntington disease.
  • To discuss its epidemiology, pathogenesis, diagnosis, and management.
  • To highlight current and future therapeutic strategies and clinical trials.

Main Methods:

  • Review of existing literature on Huntington disease.
  • Analysis of epidemiological data.
  • Discussion of genetic factors, protein aggregation, and cellular mechanisms.
  • Overview of diagnostic approaches and clinical management.
  • Summary of clinical trial outcomes and emerging therapies.

Main Results:

  • Huntington disease prevalence is higher than previously estimated and shows geographic variability.
  • CAG repeat length correlates with clinical phenotype, and genetic modifiers influence disease onset and progression.
  • Multiple pathogenic mechanisms contribute to neuronal dysfunction and death in HD.

Conclusions:

  • Effective disease-modifying therapies for Huntington disease are still lacking.
  • Significant progress is being made in understanding HD pathogenesis and developing targeted treatments, including huntingtin-lowering drugs.
  • Biomarker development is crucial for advancing future clinical trials.